Ask AI
H.R. 2851

To prohibit application of a payment limit to a drug or biological under part B of the Medicare Program based on a less costly alternative for courses of treatment begun before the change in payment.

A plain-language summary from the Congressional Research Service isn’t available yet for this bill. CRS summaries are typically posted within a few weeks of introduction.

Referred to the Subcommittee on Health and Environment.

Rep. Kennelly, Barbara B. [D-CT-1](D-CT)Sponsor
To prohibit application of a payment limit to a drug or biological under part B of the Med… — Informed